Literature DB >> 312620

Suppressor cell function in multiple sclerosis: correlation with clinical disease activity.

J P Antel, B G Arnason, M E Medof.   

Abstract

Concanavalin A (Con A)-activated suppressor cell activity was determined in multiple sclerosis (MS) patients who had been assigned to one of three subgroups, those with active disease, those recovering from a flare-up, and those with stable disease. The level of suppression induced by the Con A-activated suppressor cells on the mitogenic response of autologous peripheral blood lymphocytes was reduced in patients with active disease (3 +/- 8%) compared with stable patients (30 +/- 8%), patients recovering from a flare-up (62 +/- 5%), and controls (40 +/- 5%). As a measure of the actual amounts of suppressor factors released, the effect of supernatants from the Con A-activated cells on the proliferative activity of a dividing cell line (L cells) was determined concurrently. The inhibitory effect of supernatants from activated cells was reduced in active and stable MS patients (7 +/- 3%) compared to controls (21 +/- 4%). Three of 4 with active MS showed mildly elevated immune complex levels as measured by the Raji cell technique; each of these patients had low suppressor activity. Levamisole (1 microgram per milliliter) failed to alter suppressor cell activity in our in vitro system.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 312620     DOI: 10.1002/ana.410050406

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  39 in total

1.  Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

Authors:  K Genç; D L Dona; A T Reder
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

3.  T-lymphocyte subsets modifications in multiple sclerosis: correlation with clinical disease activity.

Authors:  M Prencipe; E Salerni; C D'Aurizio; C Marini; D Adorno; A M Berghella; P Pellegrini; F Papola; C U Casciani
Journal:  Ital J Neurol Sci       Date:  1986-12

4.  The role of the thymus in multiple sclerosis.

Authors:  V D'Andrea; G Meco; F Corvese; P F Baselice; V Ambrogi
Journal:  Ital J Neurol Sci       Date:  1989-02

5.  Defective autologous mixed lymphocyte reactivity in multiple sclerosis.

Authors:  R L Hirsch
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

Review 6.  The role of prostaglandins in altered leukocyte function in multiple sclerosis.

Authors:  P Dore-Duffy; S Y Ho; M Longo
Journal:  Springer Semin Immunopathol       Date:  1985

7.  Monoclonal antibody-defined immunoregulatory cells in multiple sclerosis cerebrospinal fluid.

Authors:  N Cashman; C Martin; J F Eizenbaum; J D Degos; M A Bach
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

8.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

9.  Long-term growth in vitro of human cerebrospinal fluid T lymphocytes.

Authors:  J B Burns; B Zweiman; R P Lisak
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

10.  Monoclonal antibody analysis of blood T-cell subsets in multiple sclerosis.

Authors:  M Zaffaroni; D Caputo; A Ghezzi; S Marforio; C L Cazzullo
Journal:  Ital J Neurol Sci       Date:  1984-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.